Trial to Study Patients in Ovarian, NSCLC and Other Cancers
XMT-1536 is Second Dolaflexin Antibody Drug Conjugate to Enter Clinical Trials
CAMBRIDGE, MA, USA I December 12, 2017 I Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) based on its proprietary Dolaflexin® platform, today announced dose administration for the first patient in a Phase 1, open-label, dose-escalation and expansion study of XMT-1536. XMT-1536 is a first-in-class ADC targeting NaPi2b, a clinically validated ADC target broadly expressed in epithelial ovarian cancer and non-squamous non-small cell lung cancer (NSCLC), as well as a number of other tumor types.
Mersana plans to enroll an initial dose-escalation cohort in patients with NaPi2b-expressing tumors in the Phase 1 study with the objective of selecting the recommended Phase 2 dose followed by three expansion cohorts. Two expansion cohorts are expected to each enroll 30 patients with ovarian cancer and non-squamous non-small cell lung cancer, while a third cohort is expected to consist of patients with rarer tumors that are known to express NaPi2b, such as papillary thyroid cancer, papillary renal cell carcinoma, endometrial cancer and salivary duct cancer.
“The initiation of this study represents a significant milestone for Mersana, as it marks the start of the company’s second clinical program within the past year,” said Donald A. Bergstrom, M.D., Ph.D., Chief Medical Officer of Mersana. “Our rapid progress from receiving IND clearance to initiating dosing of patients is indicative of the expertise of our internal team as well as the relationships with our CRO and investigator partners. Based on our exciting preclinical data, we look forward to evaluating the potential of XMT-1536 as a treatment for patients with NaPi2b-expressing cancers.”
XMT-1536 is comprised of Mersana’s Dolaflexin platform conjugated to a proprietary NaPi2b antibody. Each antibody molecule carries 10-15 molecules of Mersana’s proprietary payload featuring the Dolalock controlled-bystander effect, resulting in a balance of meaningful preclinical efficacy and preclinical tolerability. In preclinical studies, XMT-1536 induced greater than 50% median tumor regression in 10/19 (53%) primary patient-derived ovarian cancer xenograft models unselected for NaPi2b protein expression, with 10/12 (83%) tumor responses in NaPi2b-expressing models. In patient-derived NSCLC xenograft models, XMT-1536 achieved durable tumor regressions in 6/9 (75%) tested models.
For more information, please visit: https://clinicaltrials.gov/ct2/results?cond=&term=XMT-1536&cntry1=&state1=&recrs=.
About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop highly targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to patients. Mersana’s lead product candidate, XMT-1522, is in Phase 1 clinical trials in patients with advanced tumors expressing HER2, including breast cancer, non-small-cell-lung-cancer (NSCLC) and gastric cancer patients. The Company’s second product candidate, XMT-1536, entered clinical trials in late 2017. In addition, multiple partners are using Mersana’s platform to advance their ADC pipelines.
SOURCE: Mersana Therapeutics
Post Views: 14
Trial to Study Patients in Ovarian, NSCLC and Other Cancers
XMT-1536 is Second Dolaflexin Antibody Drug Conjugate to Enter Clinical Trials
CAMBRIDGE, MA, USA I December 12, 2017 I Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) based on its proprietary Dolaflexin® platform, today announced dose administration for the first patient in a Phase 1, open-label, dose-escalation and expansion study of XMT-1536. XMT-1536 is a first-in-class ADC targeting NaPi2b, a clinically validated ADC target broadly expressed in epithelial ovarian cancer and non-squamous non-small cell lung cancer (NSCLC), as well as a number of other tumor types.
Mersana plans to enroll an initial dose-escalation cohort in patients with NaPi2b-expressing tumors in the Phase 1 study with the objective of selecting the recommended Phase 2 dose followed by three expansion cohorts. Two expansion cohorts are expected to each enroll 30 patients with ovarian cancer and non-squamous non-small cell lung cancer, while a third cohort is expected to consist of patients with rarer tumors that are known to express NaPi2b, such as papillary thyroid cancer, papillary renal cell carcinoma, endometrial cancer and salivary duct cancer.
“The initiation of this study represents a significant milestone for Mersana, as it marks the start of the company’s second clinical program within the past year,” said Donald A. Bergstrom, M.D., Ph.D., Chief Medical Officer of Mersana. “Our rapid progress from receiving IND clearance to initiating dosing of patients is indicative of the expertise of our internal team as well as the relationships with our CRO and investigator partners. Based on our exciting preclinical data, we look forward to evaluating the potential of XMT-1536 as a treatment for patients with NaPi2b-expressing cancers.”
XMT-1536 is comprised of Mersana’s Dolaflexin platform conjugated to a proprietary NaPi2b antibody. Each antibody molecule carries 10-15 molecules of Mersana’s proprietary payload featuring the Dolalock controlled-bystander effect, resulting in a balance of meaningful preclinical efficacy and preclinical tolerability. In preclinical studies, XMT-1536 induced greater than 50% median tumor regression in 10/19 (53%) primary patient-derived ovarian cancer xenograft models unselected for NaPi2b protein expression, with 10/12 (83%) tumor responses in NaPi2b-expressing models. In patient-derived NSCLC xenograft models, XMT-1536 achieved durable tumor regressions in 6/9 (75%) tested models.
For more information, please visit: https://clinicaltrials.gov/ct2/results?cond=&term=XMT-1536&cntry1=&state1=&recrs=.
About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop highly targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to patients. Mersana’s lead product candidate, XMT-1522, is in Phase 1 clinical trials in patients with advanced tumors expressing HER2, including breast cancer, non-small-cell-lung-cancer (NSCLC) and gastric cancer patients. The Company’s second product candidate, XMT-1536, entered clinical trials in late 2017. In addition, multiple partners are using Mersana’s platform to advance their ADC pipelines.
SOURCE: Mersana Therapeutics
Post Views: 14
